Puretech Health (LON:PRTC)‘s stock had its “buy” rating restated by analysts at Liberum Capital in a research report issued to clients and investors on Thursday. They currently have a GBX 248 ($3.32) price objective on the stock. Liberum Capital’s target price would indicate a potential upside of 96.44% from the stock’s current price.
A number of other research analysts also recently weighed in on PRTC. Peel Hunt restated a “buy” rating and set a GBX 278 ($3.72) price objective on shares of Puretech Health in a research report on Thursday. N+1 Singer reiterated a “buy” rating on shares of Puretech Health in a research report on Thursday. Numis Securities reiterated a “buy” rating and issued a GBX 207 ($2.77) price target on shares of Puretech Health in a research report on Monday, September 25th. Finally, Jefferies Group reiterated a “buy” rating on shares of Puretech Health in a research report on Friday, November 17th. Five equities research analysts have rated the stock with a buy rating, Puretech Health currently has an average rating of “Buy” and a consensus target price of GBX 248 ($3.32).
Shares of Puretech Health (LON:PRTC) traded up GBX 1.88 ($0.03) during trading on Thursday, reaching GBX 126.25 ($1.69). 243,476 shares of the company were exchanged, compared to its average volume of 41,921. Puretech Health has a 12 month low of GBX 110 ($1.47) and a 12 month high of GBX 139 ($1.86).
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health PLC and related companies with MarketBeat.com's FREE daily email newsletter.